ENTITY

ImmuPharma Plc (IMM LN)

4
Analysis
Health CareUnited Kingdom
ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company?s lead product candidates include the Lupuzor, which is in Phase III clinical trials for the treatment of lupus, a chronic, autoimmune, and inflammatory disease; IPP-204106, an anti-cancer nucleolin antagonis peptide program that has completed Phase I/IIa clinical trials to treat cancer; IPP-201007, which is in pre-clinical development stage for the treatment of inflammatory/allergic conditions, such as asthma and rheumatoid arthritis; IPP-102199 that is in pre-clinical development stage to treat moderate and severe pain; and IPP-203101, a peptide-based antibiotic, which is in pre-clinical development stage for the treatment of lethal infections, such as methicillin-resistant staphylococcus aureus and other hospital acquired infections. Its discovery pipeline includes heterocyclic ureas scaffolds; and peptide to drug converting technology, which enhances a peptide?s plasma half-life and efficacy. ImmuPharma plc has collaboration arrangements with the Centre National de la Recherch� Scientifique; and the Institut National de la Sante et de la Recherche Medicale. The company was founded in 1999 and is headquartered in London, the United Kingdom.
more
21 Mar 2025 11:27Issuer-paid

Hybridan Small Cap Feast: 13/03/2025

The assessment has reached an advanced stage where eleven Prospecting Licenses have now been applied for, covering 7,322 square kilometres.

Logo
Hybridan
265 Views
Share
bullishONDO INSUR TECH
14 Feb 2025 02:39Issuer-paid

Hybridan Small Cap Feast: 13/02/2025

This proven innovation and expertise are now being applied to bespoke designs for the newly awarded pressure-door contract.

Logo
Hybridan
104 Views
Share
11 Jan 2025 02:00Issuer-paid

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to...

Logo
397 Views
Share
10 Jan 2025 22:18Issuer-paid

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments...

Logo
393 Views
Share
No more insights
x